Silexion Therapeutics Ltd. (SLXN) Earnings History
Net Loss6 years of earnings data (2020–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Silexion Therapeutics Ltd. (SLXN) Earnings Overview
As of November 8, 2026, Silexion Therapeutics Ltd. (SLXN) reported trailing twelve-month net income of -$14M, reflecting +97.7% year-over-year growth. The company earned $-20.31 per diluted share over the past four quarters.
Looking at the long-term picture, SLXN's historical earnings data spans multiple years. The company achieved its highest annual net income of -$195,860 in fiscal 2020.
Silexion Therapeutics Ltd. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including SRPT ($15M net income, -32.5% margin), ARWR (-$320M net income, -0.2% margin), NTLA (-$426M net income, -609.9% margin), SLXN has comparable earnings metrics. Compare SLXN vs SRPT →
SLXN Earnings vs Peers
Earnings metrics vs comparable public companies
SLXN Historical Earnings Data (2020–2025)
6 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$12M | +27.6% | $12M | $-89.60 | - | - |
| 2024 | -$16M | -232.7% | -$13M | $-3953.62 | - | - |
| 2023 | -$5M | -53.7% | -$5M | $-6634.98 | - | - |
| 2022 | -$3M | -325.7% | -$4M | $52.37 | - | - |
| 2021 | $-755,218 | -285.6% | $-943,933 | $-68.63 | - | - |
| 2020 | $-195,860 | - | $-195,860 | $-17.79 | - | - |
Download Data
Export SLXN earnings history in CSV or JSON format
Free sign-in required to download data
SLXN Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
6+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
SLXN — Frequently Asked Questions
Quick answers to the most common questions about buying SLXN stock.
What is SLXN earnings per share (EPS)?
SLXN trailing twelve-month (TTM) diluted EPS is $-20.31, reflecting +97.7% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2020 to 2025 is available in the table on this page.
What is Silexion Therapeutics Ltd.'s net income?
Silexion Therapeutics Ltd. (SLXN) trailing twelve-month net income is $-14M as of 2025. Earnings grew +97.7% year-over-year.
Is SLXN profitable?
SLXN is not currently profitable on a TTM basis, reporting a net loss of $-14M. Net margin is N/A. Investors should monitor for a return to profitability.
What is SLXN's earnings growth rate?
SLXN compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2020 to 2025.
What are SLXN's profit margins?
Silexion Therapeutics Ltd. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -457.6%.
Is SLXN growing earnings?
Yes, SLXN earnings are accelerating — EPS growth of +97.7% exceeds the 5-year CAGR of N/A. TTM net income reached $-14M. Earnings momentum is strengthening.
What was SLXN's best earnings year?
Silexion Therapeutics Ltd.'s highest annual net income on record is $-195860.00, achieved in fiscal year 2020. Earnings history on this page spans 2020 to 2025 and includes all annual and quarterly figures.
What were SLXN's earnings last quarter?
SLXN's most recent reported quarter was Q2 2026. Net income was $-4M with diluted EPS of $-5.17. For a full breakdown of all quarters, see the quarterly earnings table on this page.